Qurient Co Ltd (115180)

Currency in KRW
21,800
+50(+0.23%)
Closed·
Advertisement
115180 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20,75022,050
52 wk Range
11,66062,900
Key Statistics
Bid/Ask
21,750.00 / 21,800.00
Prev. Close
21,750
Open
21,050
Day's Range
20,750-22,050
52 wk Range
11,660-62,900
Volume
91.24K
Average Volume (3m)
182.11K
1-Year Change
82.4268%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
115180 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Qurient Co Ltd News & Analysis

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Earnings

Latest Release
14/08/2026
EPS / Forecast
-340.00 / --
Revenue / Forecast
1.91B / --
EPS Revisions
Last 90 days

Qurient (115180) Income Statement & Profits

Compare 115180 to Peers and Sector

Metrics to compare
115180
Peers
Sector
Relationship
P/E Ratio
−23.1x−12.4x−0.4x
PEG Ratio
0.52−0.210.00
Price/Book
52.2x2.4x2.6x
Price / LTM Sales
125.4x14.1x3.0x
Upside (Analyst Target)
-47.2%55.1%
Fair Value Upside
Unlock4.8%8.2%Unlock

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.16M2.84%25.13B
Other Institutional Investors
9.37M23.05%203.83B
Public Companies & Retail Investors
30.14M74.11%655.49B
Total
40.66M100.00%884.45B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
DongKoo Bio & Pharma Co., Ltd.11.22%4,563,87299,264,216
KEYSTONE Private Equity Co., Ltd.4.00%1,626,89835,385,032

People Also Watch

16,850
950160
-2.38%
8,540
358570
+3.52%
146,000
087010
-3.69%
46,800
007340
+1.30%
90,000
237690
-1.96%

FAQ

What Is the Qurient (KOSDAQ: 115180) Share Price Today?

The Qurient stock price today is 21,800 KRW.

What Stock Exchange Does Qurient (115180) Trade On?

Qurient is listed and trades on the KOSDAQ.

What Is the Ticker (Stock Symbol) for Qurient?

The stock symbol (also called a 'ticker') for Qurient is "115180."

What Is the Current Qurient Market Capitalisation?

As of today, Qurient (KOSDAQ: 115180) market cap is 886.49B KRW.

What Is Qurient's (115180) Earnings Per Share (TTM)?

The Qurient EPS is currently -1,057 (Trailing Twelve Months).

Is 115180 a Buy or Sell From a Technical Analyst Perspective?

Based on today's Qurient moving averages and other technical indicators, the daily buy/sell signal for 115180 stock is Strong Sell.

How Many Times Has Qurient Stock Split?

Qurient has split 1 times. (See the 115180 stock split history page for full effective split date and price information.)

What is the current trading status of Qurient (KOSDAQ: 115180)?

As of 13/09/2026, Qurient (115180) is trading at a share price of 21,800 KRW, with a previous close of 21,750 KRW. The stock has fluctuated within a day range of 20,750 KRW to 22,050 KRW, while its 52-week range spans from 11,660 KRW to 62,900 KRW.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.